Taking into account all relevant factors, TherapeuticsMD, Inc. (NASDAQ:TXMD) scores 80% Sell on the technical side. The share price is also flashing a Hold from the Barchart TrendSpotter trading system. Investors starting out on a short-term path of investing should know that short terms indicators for TXMD averaged 50% Sell with an average daily trading volume over the past 20 days at 3860266 shares. Those using medium-term investment strategies, the shares have overall a 1% Sell signal while the 50-day average daily volume remained almost 3454655 shares. It’s also important to note that the stock, whose average daily volume over the 100 days as of this piece was 3435384 shares, is signaling100% Sell for long term investors.
The stock is lingering around the initial support level of $2.43. After this, the following support is at the zone of $2.31. Up until the time the TXMD stock hit levels beyond the current one, bulls should have no alarm. In terms of its momentum, the stock’s RSI hit 50.95 on the daily chart, and this may be a cause for concern. In case the price goes below $2.31 level on closing basis, there may be more profit booking with the stock growing weaker. Still, getting to the $2.68 level may cause a pull-back move approaching $2.81 mark.
TherapeuticsMD, Inc. (TXMD) is most likely going to rise 269.8 percent in the coming 12 months, as per price target approximations compiled by finviz. Nevertheless, they have set the price target at a $16 as 12-month high price target. This represents a whopping 553.06 percent increase from the current trading price of shares. The 52-week median price target given by the analysts is $7, which means a return possibility of 185.71 percent in comparison with the closing price of the stock of $2.45 in recent trading session. The lowest price set for the stock is $2.5 which is just above 2.04 percent from TXMD share’s price at the end of session.
Let’s take a glimpse at some insider activity at TherapeuticsMD, Inc. (NASDAQ:TXMD) and observe the pattern. The earliest insider trade happened on 10/25/2019. Bernick Brian gathered a total of 36 thousand shares of the firm at average share price of $2.75. The total amount for the purchase was set at $99 thousand. On completing this exchange, the Director account balance was 6.66 million shares. The stock lost -3.64 percent from that insider purchase. On 10/25/2019, Finizio Robert G, CEO, did a purchase of 72 thousand shares at a price of $2.75 per share. This increased 198 thousand shares to the insider’s fortune and the stock experienced a -3.64 percent retreat in price since the news became public. This exchange saw 20.33 million shares get into the CEO account. On 10/25/2019, President/Secretary Milligan John C.K. IV recorded a purchase transaction valued at $198 thousand. The purchase at $2.75 a share has added 72 thousand shares into the insider’s portfolio position. Meanwhile, shares price witnessed -3.64 percent decrease since the transaction reporting date. The company insider is left with 5.56 million shares remaining in the account. Milligan John C.K. IV, who works as President/Secretary at the company, performed a purchase of 72 thousand shares in a transaction worth $198 thousand. The acquisition recorded on 10/25/2019 was priced at $2.75 per share. The stock price plunged -3.64 percent since the transaction. Milligan John C.K. IV currently holds a stake of 5.56 million in TXMD stock which is worth $13.63 million after the insider buying.
In the recent trading session, TherapeuticsMD, Inc. (NASDAQ:TXMD) shares lost -3.92% or -0.1 points to reach at $2.45 with a thin trading volume of 1.112 million shares. It opened the trading session at $2.46, the shares rose to $2.69 and dropped to $2.44, the range by which the price of stock traded the whole session. The company now has a market cap of $680 million and currently has 266.54 million outstanding shares. TherapeuticsMD, Inc. (TXMD) stock has accumulated 10.87 percent of market value in 21 trading days.
Stock analysts at Guggenheim, assumed coverage of shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) with Buy recommendation, according to their opinion released on December 02.
TXMD stock’s trailing 3-year beta is 1.62, meaning there will be a greater rate of return, although posing a higher risk. The part of a firm’s profit given to each outstanding share of regular stock was -$0.69 share in the trailing 52 weeks. The stock’s value surged 5.37 percent year to date (YTD) compared to a decline of -50.29 percent in 52 week’s period. The firm’s shares are still trading -59.77 percent below its 1-year high of $6.09 and 34.62 percent up from 52-week low of $1.82. The average consensus ranking on the company is 1.9, on a ranging where 5 is equal to a consensus sell rating. In other words, the mean analyst recommendations are ranking this stock as a buy.
TherapeuticsMD, Inc. (TXMD) shares are trading at a P/E ratio of -3.39 times earnings posted in the trailing 12 months. The industry TXMD deals with has an average P/E of 32.03. Its P/B ratio is standing at -19.53X compared to the 7.25 industry average. It is additionally sporting a 22.55 on the Price-to-Sales ratio, compared to the industry’s P/S average of 0.95. TherapeuticsMD, Inc. has a 88.7% gross profit margin.
Past records have indicated that shares in TherapeuticsMD, Inc. declined on 10 different earnings reaction days and we have yet to see whether this trend will play out and remain in place when the company reports upcoming earnings. Investors will get the next hint of TXMD’s Q4 earnings on February 24. Analysts are predicting revenue to climb 152.3 percent to $12.84M in the financial fourth quarter, while EPS will soar by about 11.76 percent to -$0.19 per share. In the last quarter, it’s earnings of -$0.13 per share came better than the -$0.16764, adjusted, expected by Thomson Reuters consensus estimate. Revenue for the quarter was $5.09M, topping the $4.48M analysts had expected. Earnings are seen to rise by -57.5 percent this year, 26 percent in the coming year and the trend continues by 19.5 percent every year in the next 5 years.